Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

PURPOSE Tumor-intrinsic features may render large B-cell lymphoma (LBCL) insensitive to CD19-directed chimeric antigen receptor T cells (CAR-T). We hypothesized that TP53 genomic alterations are detrimental to response outcomes in LBCL treated with CD19-CAR-T. MATERIALS AND METHODS Patients with LBCL treated with CD19-CAR-T were included. Targeted next-generation sequencing was performed on...

  • Insightful study that highlights how TP53 continues to be an adverse prognostic factor in DLBCL even with CAR-T therapies.